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Abstract
For most chronic medical conditions, multiple medications are available and prescribers often have limited
evidence about which therapy is likely to be the most effective and safe for an individual patient. As many patients
are exposed every day to medicines that may be less effective than available alternatives, this is of public health
importance. Cluster randomised trials of prescribing policy offer an opportunity to rapidly obtain evidence of
comparative effectiveness and safety. These trials can pose a low risk to patients and cause minimal disruption to
usual care. Despite the potential scientific value of this approach, there remain valid concerns about consent,
medication switching and the use of routinely collected data in research. We discuss these concerns with reference
to an ongoing pilot study (Evaluating Diuretics in Normal Care (EVIDENCE) - a cluster randomised evaluation of
hypertension prescribing policy, ISRCTN 46635087, registered 11 August 2017).
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1. Background and aims
The World Health Organization (WHO) has highlighted
the importance of drug safety research in providing doc-
tors with evidence to inform prescribing decisions [1].
For any medical condition, there may be several licensed
treatment options with similar modes of action. Add-
itionally, the evidence used to support licensing applica-
tions is usually from randomised controlled trials of
limited duration and using non-representative care path-
ways [2]. External validity is further limited by trial par-
ticipation being restricted to exclude individuals with
comorbidities. Thus, prescribers are faced with a choice
between multiple medicines but with limited applicable
comparative safety and effectiveness evidence. In the ab-
sence of such evidence, prescribing choices are made on
the basis of cost, anecdotal experience or non-evidence-
based guidelines [3].
Comparative effectiveness research using observational
methods can be used to fill these evidence gaps by
studying medicines when they are already in use. These
studies often include much larger numbers of patients,
who may have more complex illness and multimorbidity,
for longer follow-up periods, making up for some of the
generalisability shortcomings of interventional pre-
licensing studies. However, they can be difficult to inter-
pret because of data quality concerns, unmeasured con-
founders and baseline imbalances of dependent
variables, all of which may bias estimates of treatment
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effect. Observational research is often considered by pre-
scribers to be insufficient to change practice. Newer ob-
servational methods – such as propensity score
matching, instrumental variables, marginal structural
models and sensitivity analyses – aimed at improving
causal inference should improve this situation [4–6]. But
randomisation, by significantly reducing baseline imbal-
ance, allows researchers to make stronger claims of
cause and effect. Post-licensing randomised drug com-
parisons remain uncommon as there is little incentive
for a company to test their product against a competi-
tor’s [7]. Surveillance systems, such as the UK Yellow
Card Scheme [8], are designed to detect safety signals
post-licensing but rely on individuals recognising events
as potential adverse drug effects. Therefore, it is vital for
public health that robust research frameworks be devel-
oped to monitor, evaluate and compare the safety and
effectiveness of medicines after licensing. We describe a
cluster randomised study design that could be used
within such a framework, when clinically useful evidence
from more traditional sources is not available, and con-
sider the ethical implications of this approach.
2. Discussion
2.1. Cluster randomisation of prescribing policy
Traditional randomised controlled trials, usually consid-
ered the gold standard for comparing treatments, are ex-
pensive and time-consuming; in 2012 the estimated
average cost per patient in a UK trial was £7890 [9].
Using only this type of trial to compare the expanding
range of available drugs is not feasible. Cluster rando-
mised trials, where interventions are applied to groups
of individuals, are more economical to implement and
can be scaled up readily across health services, allowing
more efficient and equitable use of finite research re-
sources. A major advantage of cluster randomised trials
over individually randomised trials is that the former im-
prove generalisability, as randomisation can include all
individuals who would be eligible for an intervention
and not just those who choose to participate. Trials
using an opt-out recruitment approach, or with a waiver
of consent, can study patient populations more repre-
sentative of people with the condition in question,
whereas opt-in only recruitment results in healthier,
smaller, and non-representative study populations [10,
11]. These advantages must be balanced against a need
for careful statistical planning to take account of
intracluster correlation and baseline covariate imbalance
[12–14]. A study that produces highly generalisable re-
sults may be seen as more directly relevant to practice
and more likely to effect change in prescriber behaviour.
Cluster randomised trials of prescribing policy are one
pragmatic solution to comparing drug treatments that
are already licensed and in use within a health-care
system but that lack direct comparative effectiveness data.
Randomisation is not performed on individuals but on
existing groups of individuals, such as hospitals, clinics, or
primary care practices. The intervention is prescribing
policy applied at the cluster level. This approach to com-
parative effectiveness evaluation was suggested by Sabin
et al. in their discussion of the ethics of cluster rando-
mised trials [15]. The method was tested by McCarren
et al. in their report on the feasibility of using cluster ran-
domisation to compare chlorthalidone and hydrochlortha-
lidone [16], randomly assigning health-care providers to
favouring one agent over the other for any new prescrip-
tions of thiazide diuretics. That study was granted a waiver
of individual consent to broaden inclusion. The approach
was accepted by providers, but over the 9-month study,
only 138 patients (at 18 sites) were newly prescribed a
thiazide medication. Clearly, applying randomisation to
new medication starts only would require a very large
number of sites to be randomly assigned to achieve statis-
tical significance for most clinical outcomes. We propose
a further development of this method that uses mecha-
nisms for the routine switching of long-term prescribed
medications that already exist within the UK National
Health Service (NHS).
2.2. Prescribing policies and medication switching
Routine changes to prescribing policy are common in the
NHS and often occur when there are price differences be-
tween similar drugs, supply problems, or newly available
evidence. Local, regional or national NHS bodies make de-
cisions on preferred prescribing choices via reimburse-
ment, formularies or guidelines. Individual prescribers in
the NHS remain free to prescribe as they see fit, and there
are limitations only for very costly or high-risk treatments.
Prescribing policy changes can result in changes being
made to a patient’s existing routine medications and re-
quire no ethical approval or individual patient consent, al-
though a general notification of the change is sometimes
provided [17]. These bulk medication changes, referred to
as “switches” within the NHS, can be met with suspicion
or confusion, and patients sometimes object to changes
towards cheaper generic drugs [17]. However, the public
is generally accepting of medications being changed to
evaluate safety or effectiveness. When asked in a survey
how they would react upon receiving a letter informing
them of a medication change, 61% of UK respondents said
they would be "happy" or they "would not mind" [18].
When the reason for the change was given as “to find out
which drug works better”, 67% stated they would be
"happy" or they "would not mind" [18].
2.3. Example study
We have piloted the methods of a cluster randomised
trial of prescribing policy to compare two commonly
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used diuretics in the management of hypertension,
bendroflumethiazide and indapamide. The aim of the
pilot was to test the feasibility and acceptability of the
intervention and study procedures. Twenty-nine medical
practices in Scotland have been randomly assigned to a
prescribing policy specifying which study drug should be
first-line. Practices agreed to adopt the assigned policy
for future prescribing and existing routine prescriptions
have been switched accordingly. Doctors remain free to
select the most appropriate medication for their patients.
All patients eligible for a potential medication switch
have been informed by letter of the policy change. The
letter explains the reason for any medication changes
and directs patients to visit the study website or contact
the study team (by telephone or email) to find out more
about the study or to opt out of the proposed medica-
tion change. De-identified routinely collected prescribing
and hospitalisation data will be used to assess post-
randomisation prescribing and baseline covariates. In
the full study, these data will be used to identify clinic-
ally important outcomes, including cardiovascular hospi-
talisations and mortality.
Cluster trials of medicines are a relatively new concept
in health care, and few specific formal ethical and regula-
tory guidelines are available for researchers. They have
attracted criticism over ethical concerns about identifica-
tion of the participant and the need for individual
informed consent [19, 20]. Cluster randomisation of pre-
scribing policy raises additional concerns around medica-
tion switching and the use of routinely collected data.
2.4. Informed consent
Ethical guidelines such as the Ottawa Statement [21]
and those produced by the Council for International Or-
ganizations of Medical Sciences (CIOMS) and the WHO
have considered cluster trials to be a distinct trial type
[22]. One important area of ethical debate is whether in-
dividuals affected by interventions applied at the cluster
level should be considered participants and whether they
should be subject to individual informed consent re-
quirements [23]. In the example study described, it is
clear that patients are directly affected by the policy ran-
domisation and that it is feasible for an individual pa-
tient to opt out of having their medication changed
without affecting the rights of other patients. For this
reason, we have considered them to be participants. The
primary concern, therefore, is whether formal opt-in in-
dividual consent is required in this study design.
Informed consent aims to ensure that an individual is
free to choose to participate, has sufficient information
about the research, and is capable of providing consent.
Individual informed consent is often considered an abso-
lute ethical requirement in clinical research. Indeed,
some believe a lack of individual informed consent
means that a study cannot ethically proceed [24]. Cur-
rently accepted methods of informing patients about re-
search studies are not always effective at achieving these
aims [25, 26]. Also, obtaining individual consent can sig-
nificantly add to the cost and duration of a study [27–
30] and may damage the generalisability of findings by
restricting recruitment to more motivated and literate
participants [31, 32]. The blanket application of ethical
guidelines to low-risk situations, such as where licensed
medications already in common usage are being com-
pared, has been criticised as hindering valuable research
[33–35]. Consequently, there have been discussions
about whether there is a need to modify existing consent
regulations, such as opt-out consent, for health-care re-
search considered to be of low risk to patients [27, 33].
Another suggestion is a policy of general notification to
patients in health-care systems that certain decisions
about care may be subject to research [36].
Any requirement to gain individual informed consent
in the context of policy randomisation applied at the
practice level should be balanced against other ethical
concerns. Doctors and patients need evidence to make
informed decisions. All health-care decisions require the
balancing of potential benefits and risks, but lack of evi-
dence for the relative effectiveness of one drug over an-
other means that choices between treatments cannot be
fully evidence-based. Although every prescribing deci-
sion made under these conditions carries some risk,
health-care providers who engage with cluster rando-
mised prescribing policy studies would be doing so in
the best interests of their future patients. Clinicians
could even be accused of acting unethically for failing to
acknowledge existing uncertainty about the best choice
of treatment and not informing a patient of the inherent
risk of non-evidence-based treatments [37].
Cluster randomised trials of prescribing policy present
an opportunity to carry out societally important research
but they must be designed to operate within current eth-
ical and legal frameworks. This is despite the lack of
consensus amongst researchers, regulators and ethicists
on when individual informed consent to either policy-
level interventions or data collection is necessary or es-
sential [20, 38, 39].
While prescribing policies affect groups of patients, we
believe that clinicians and their patients should be in-
formed of the reason(s) for policy changes and reserve
the right to choose whether to follow a prescribing pol-
icy in individual treatment decisions. In this way, the in-
dividual autonomy of both prescriber and patient can be
preserved. Patients should never be forced into research
participation, but, for studies comparing currently ac-
cepted standards of care, it may be appropriate that pa-
tients simply be informed that research is taking place
and be given the right to withdraw from the intervention
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or from data collection (or both) without affecting their
care [27]. The right to withdraw from the intervention
in the study method we have described is a scientific
trade-off – made to maintain ethical integrity – that will
introduce a degree of selection bias.
2.5. Routinely collected data
Routine health-care data have great potential for clinical
trials with a major advantage to cluster randomised pol-
icy evaluation of avoiding disruption to usual care [40].
It has been argued that patients have a moral responsi-
bility to allow access to their data to improve the health-
care system for all [35]. However, the use of routinely
collected medical data for research does raise additional
ethical and regulatory concerns [40]. Potential risks in
using routinely collected data include loss of patient
confidentiality and loss of patient trust in research [40].
Existing programmes do allow patients some choice
about whether their data can be used for reasons not
directly related to their own care. For example, the NHS
England National Data Opt-out has been exercised by
2.74% of patients [41]. There are currently no mecha-
nisms for patients in the UK to choose which studies
may use their data.
3. Conclusions
The method we have outlined above could play just one
part in a comprehensive medicines safety and effectiveness
programme. It is most suitable for comparing long-term
outcomes for multiple similar drugs already in widespread
use but could be adapted to compare new treatments
against existing standards of care (e.g., evaluating a
planned introduction of a newly licensed medication). The
method would be less suitable for use in health systems
where patients and practitioners are not familiar with in-
stitutional prescribing policies and routine medication
switching. Implementing this methodology on a large
scale will require significant efforts to engage prescribers
and patients. Each proposed medicine comparison would
still need to be considered on a case-by-case basis by an
appropriate ethical review body to ensure that the rights
of individuals are not unduly limited.
Although this method should improve external validity
and does increase the feasibility of large-scale compara-
tive effectiveness research within the NHS, it is not yet
known to what extent patients choosing not to accept
proposed medication changes might cause problematic
selection bias. The results of our pilot study should in-
form this consideration. This study design is a hybrid
between randomised controlled trial and observational
methods. Whether this is an acceptable compromise re-
mains a matter for debate.
There is an unmet need for comparative effectiveness
research to determine the best medicine for many
conditions, and randomised prescribing policy evalua-
tions are an opportunity to efficiently meet this need.
This type of trial challenges traditional research ethics
and consent standards. While ethical guidelines are im-
portant to protect individual patient rights and welfare,
facilitating research that could resolve medical uncer-
tainties for society as a whole should be of at least equal
concern. From a public health perspective, the current
situation, where patients are routinely exposed to medi-
cines that have never been compared directly against
each other, is neither clinically nor ethically acceptable.
The pilot study we have described above, conducted within
the Scottish NHS, proposes one way to address this problem.
This study design integrates with local health-care practice
with the key difference of policy allocation being actively
managed by randomisation and clinical outcomes being for-
mally assessed. Further development of this methodology
could allow for comparisons of multiple interventions to take
place simultaneously within health-care systems.
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